Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Pooled Safety Analysis from Phase I-III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib

Pier Luigi Zinzani, Muhit Özcan, Marcelo Capra, Armando Santoro, Panayiotis Panayiotidis, Krimo Bouabdallah, Wojciech Jurczak, Charles Phelps, Florian JR Hiemeyer, Lidia Mongay Soler, Jose Garcia-Vargas, Barrett H. Childs, Georg Lenz, Matthew J. Matasar, Martin Dreyling

Blood (2022) 140 (Supplement 1): 6470–6473.

https://doi.org/10.1182/blood-2022-167368

Published: 2022

Journal Articles

Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma

Martin Dreyling, MD, Panayiotis Panayiotidis, MD, George A Follows, MD PhD, Luigina Mollica, MD FRCPC, PhD, Arnon Nagler, MD MSc, Muhit Özcan, MD, Armando Santoro, Don Stevens, MD, David Trevarthen, MD, Florian Hiemeyer, MSc, Li Liu, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Pier Luigi Zinzani, MD PhD

Blood (2019) 134 (Supplement_1): 1531.

https://doi.org/10.1182/blood-2019-121932

Published: 2019

Journal Articles

Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies

Pier Luigi Zinzani, MD, Armando Santoro, Luigina Mollica, MD FRCPC, PhD, Sirpa Leppä, MD PhD, George A Follows, MD PhD, Georg Lenz, MD, Won Seog Kim, MD PhD, Arnon Nagler, MD MSc, Panayiotis Panayiotidis, MD, Judit Demeter, MD PhD Dr. Sci, Franck Morschhauser, MD, Javier Munoz, MD MS, FACP, Ashok Miriyala, MD, Alice Benson, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Martin Dreyling, MD

Blood (2019) 134 (Supplement_1): 4009.

https://doi.org/10.1182/blood-2019-131779

Published: 2019

Journal Articles

Outcomes for Patients with High-Risk Relapsed or Refractory Indolent B-Cell Lymphoma Treated with Copanlisib in the CHRONOS-1 Study

Armando Santoro, MD, Luigina Mollica, MD PhD, Sirpa Leppa, MD Prof, George A Follows, MD PhD, Georg Lenz, Won Seog Kim, MD PhD, Arnon Nagler, MD, Maria Dimou, MD PhD, Judit Demeter, MD PhD Dr. Sci, Massimo Magagnoli, MD, Liana Rodrigues, MD, Oliver Wirtz, MSc, Florian Hiemeyer, MSc, Li Liu, PhD, Karl Koechert, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Pier Luigi Zinzani, MD, Martin H. Dreyling, MD PhD

Blood (2018) 132 (Supplement 1): 395.

https://doi.org/10.1182/blood-2018-99-116715

Published: 2018

Journal Articles

Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 1595.

https://doi.org/10.1182/blood-2018-99-114842

Published: 2018

Journal Articles

Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Pier Luigi Zinzani, MD, Armando Santoro, MD, Luigina Mollica, MD FRCPC, PhD, Sirpa Leppä, MD PhD, George A Follows, MD PhD, Georg Lenz, Won Seog Kim, MD PhD, Arnon Nagler, MD, Panayiotis Panayiotidis, MD PhD, Judit Demeter, MD PhD Dr. Sci, Franck Morschhauser, MD, Liana Rodrigues, MD, John Reeves, PhD MS, Florian Hiemeyer, MSc, Ashok Miriyala, MD, Jose Garcia-Vargas, MD, Barrett H. Childs, MD, Martin H. Dreyling, MD PhD

Blood (2018) 132 (Supplement 1): 1613.

https://doi.org/10.1182/blood-2018-99-117063

Published: 2018

Journal Articles

Efficacy of Copanlisib Monotherapy in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Subset Analysis from the CHRONOS-1 Trial

Martin Dreyling, MD PhD, Panayiotis Panayiotidis, MD PhD, Miklos Egyed, MD PhD, George Follows, MA, PhD FRCP, FRCPath, BM, BCh, Luigina Mollica, MD PhD, Arnon Nagler, MD, Muhit Ozcan, MD, Armando Santoro, MD, Tatiane Ishida, MD, Cindy Lu, PhD, Florian Hiemeyer, MSc, Jose Garcia-Vargas, MD, Barrett H. Childs, MD, Pier Luigi Zinzani, MD PhD

Blood (2017) 130 (Supplement 1): 4053.

https://doi.org/10.1182/blood.V130.Suppl_1.4053.4053

Published: 2017

Journal Articles

Pooled Safety Analysis from Phase I and II Studies for Patients with Relapsed Indolent Non-Hodgkin's Lymphoma Treated with Intravenous Copanlisib

Pier Luigi Zinzani, MD PhD, Amita Patnaik, MD FRCP, Franck Morschhauser, MD PhD, Gilles Andre Salles, MD PhD, Armando Santoro, MD, Luigina Mollica, MD PhD, Krimo Bouabdallah, MD, David Cunningham, MD FRCP, Sirpa Leppa, MD, George Follows, MA, PhD FRCP, FRCPath, BM, BCh, Alice Benson, PhD, Peter Bonata, PhD, Isabelle Genvresse, MD, Ashok Miriyala, MD, Aruna Mehra, MD, Jose Garcia-Vargas, MD, Barrett H. Childs, MD, Martin Dreyling, MD PhD

Blood (2017) 130 (Supplement 1): 4042.

https://doi.org/10.1182/blood.V130.Suppl_1.4042.4042

Published: 2017

Journal Articles

Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe Toxicities

Blood (2017) 130 (Supplement 1): 2777.

https://doi.org/10.1182/blood.V130.Suppl_1.2777.2777

Published: 2017

Journal Articles

Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: Early Clinical Experience

Donna Weber, Ashraf Z. Badros, Sundar Jagannath, David Siegel, Victoria Richon, Syed Rizvi, Jose Garcia-Vargas, David Reiser, Kenneth C. Anderson

Blood (2008) 112 (11): 871.

https://doi.org/10.1182/blood.V112.11.871.871

Published: 2008

Journal Articles

A Phase I Study of Vorinostat in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

David Siegel, Donna Weber, MD, Constantine S. Mitsiades, MD, PhD, Syed Rizvi, Jose Garcia-Vargas, Jason Howe, David Reiser, Kenneth C. Anderson, MD, Paul Richardson, MD

Blood (2008) 112 (11): 3705.

https://doi.org/10.1182/blood.V112.11.3705.3705

Published: 2008

Journal Articles

Combination of Vorinostat Plus Bortezomib for the Treatment of Patients with Multiple Myeloma Who Have Previously Received Bortezomib

Donna M. Weber, Sundar Jagannath, MD, Ronald Sobecks, Gary Schiller, Lisa Chiacchierini, David Reiser, Carol Oerth, Jose Garcia-Vargas, Syed Rizvi

Blood (2008) 112 (11): 3711.

https://doi.org/10.1182/blood.V112.11.3711.3711

Published: 2008

Journal Articles

A Randomized Phase IIa Study of Vorinostat in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes: Preliminary Results

Guillermo Garcia-Manero, MD, Lewis B. Silverman, MD, Ivana Gojo, MD, Laura Michaelis, MD, Simrit Parmar, Stuart L Goldberg, Hagop M. Kantarjian, Jose Garcia-Vargas, Syed Rizvi, Karl Heath, Azra Raza

Blood (2008) 112 (11): 5084.

https://doi.org/10.1182/blood.V112.11.5084.5084

Published: 2008

Journal Articles

Phase I Study of Vorinostat in Combination with Decitabine in Patients with Relapsed or Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Mark Kirschbaum, Ivana Gojo, Stuart L Goldberg, Lisa Kujawski, Ehab Atallah, Peter Marks, Jose Garcia- Vargas, Syed Rizvi, Donna Di Gravio, Janet Ahern, Jean-Pierre Issa

Blood (2008) 112 (11): 3651.

https://doi.org/10.1182/blood.V112.11.3651.3651

Published: 2008

NARROW

Pooled Safety Analysis from Phase I-III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib

Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma

Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies

Outcomes for Patients with High-Risk Relapsed or Refractory Indolent B-Cell Lymphoma Treated with Copanlisib in the CHRONOS-1 Study

Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Efficacy of Copanlisib Monotherapy in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Subset Analysis from the CHRONOS-1 Trial

Pooled Safety Analysis from Phase I and II Studies for Patients with Relapsed Indolent Non-Hodgkin's Lymphoma Treated with Intravenous Copanlisib

Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe Toxicities

Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: Early Clinical Experience

A Phase I Study of Vorinostat in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Combination of Vorinostat Plus Bortezomib for the Treatment of Patients with Multiple Myeloma Who Have Previously Received Bortezomib

A Randomized Phase IIa Study of Vorinostat in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes: Preliminary Results

Phase I Study of Vorinostat in Combination with Decitabine in Patients with Relapsed or Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only